Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A recent working group convened by the World Health Organization recommended that time to first or only episode of clinical malaria should be used to evaluate vaccine efficacy in phase III trials. However, calculating vaccine efficacy based on this endpoint misses important aspects of malaria disease and transmission. Here, we discuss the gaps that this approach leaves in predicting the potential public health impact of a vaccine and the challenges faced by vaccine trial designers. We examine the implications of current vaccine trial design on effectiveness studies and the next generation of malaria vaccines.

Original publication

DOI

10.1111/j.1365-3024.2009.01144.x

Type

Journal article

Journal

Parasite Immunol

Publication Date

09/2009

Volume

31

Pages

574 - 581

Keywords

Biomarkers, Clinical Trials, Phase III as Topic, Humans, Malaria, Malaria Vaccines, Research Design, Treatment Outcome